Spots Global Cancer Trial Database for vorinostat
Every month we try and update this database with for vorinostat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | NCT00798720 | Carcinoma, Non ... | vorinostat bortezomib | 18 Years - | University of Wisconsin, Madison | |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT01153672 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat laboratory biom... biopsy F-18 16 alpha-f... positron emissi... anastrozole letrozole exemestane gene expression... | 18 Years - | University of Washington | |
| Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease | NCT04339751 | Cushing's Disea... | Vorinostat | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer | NCT00719875 | Advanced Breast... | Vorinostat | 18 Years - | Yale University | |
| Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer | NCT01413750 | Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Paclitaxel Carboplatin Vorinostat Placebo Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | NCT03150329 | Grade 3b Follic... Recurrent B-Cel... Recurrent Class... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Prima... Recurrent Trans... Refractory B-Ce... Refractory Clas... Refractory Diff... Refractory Foll... Refractory Prim... Refractory Tran... | Laboratory Biom... Pembrolizumab Vorinostat | 18 Years - | City of Hope Medical Center | |
| Reversing Therapy Resistance With Epigenetic-Immune Modification | NCT02395627 | Breast Neoplasm... | Tamoxifen Vorinostat Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma | NCT01879085 | Sarcoma | Docetaxel Gemcitabine Vorinostat Pegfilgrastim | 18 Years - | University of Pittsburgh | |
| Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00948064 | Leukemia | Vorinostat Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Reversing Therapy Resistance With Epigenetic-Immune Modification | NCT02395627 | Breast Neoplasm... | Tamoxifen Vorinostat Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors | NCT00138177 | Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unspecified Adu... | oxaliplatin leucovorin calc... vorinostat fluorouracil | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT00818649 | Leukemia Myelodysplastic... | bortezomib vorinostat | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) | NCT00972842 | Peripheral T-Ce... | Vorinostat, Len... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant | NCT00810602 | Hematologic Mal... Graft vs Host D... | reduced intensi... tacrolimus (sta... mycophenolate (... vorinostat | 18 Years - | University of Michigan Rogel Cancer Center | |
| Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00729118 | Multiple Myelom... Plasma Cell Neo... | lenalidomide vorinostat | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | NCT03259503 | Recurrent Diffu... Recurrent T-Cel... Refractory Diff... Refractory Hodg... Refractory T-Ce... | Busulfan Gemcitabine Melphalan Olaparib Peripheral Bloo... Pharmacokinetic... Rituximab Vorinostat | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | NCT01266031 | Malignant Gliom... Recurrent Gliob... | vorinostat bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer | NCT00735826 | Aerodigestive T... Lung Cancer Esophageal Canc... Head and Neck C... | Vorinostat | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma | NCT01342757 | Adult Glioblast... Depression Recurrent Adult... | vorinostat temozolomide magnetic resona... survey administ... | 18 Years - | National Cancer Institute (NCI) | |
| Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) | NCT00486720 | Myelodysplastic... Blood Disease Bone Marrow Dis... | vorinostat vorinostat | 18 Years - | Merck Sharp & Dohme LLC | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer | NCT00365599 | Breast Cancer | suberoylanilide... tamoxifen citra... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | NCT02943642 | Mycosis Fungoid... | A-dmDT390-bisFv... Vorinostat | 18 Years - | Angimmune LLC | |
| Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) | NCT00918489 | Soft Tissue Sar... | Vorinostat | 18 Years - | Heidelberg University | |
| Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | NCT04190056 | Anatomic Stage ... Prognostic Stag... | Pembrolizumab Tamoxifen Vorinostat | 18 Years - | University of California, San Francisco | |
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | NCT03742245 | Breast Cancer M... Breast Cancer | Olaparib Vorinostat | 18 Years - | The Methodist Hospital Research Institute | |
| Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases | NCT00838929 | Brain Metastase... | Vorinostat Radiation Thera... | 18 Years - | Thomas Jefferson University | |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | NCT00138203 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | vorinostat laboratory biom... | 19 Years - | National Cancer Institute (NCI) | |
| Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | NCT00330161 | Recurrent Prost... Stage IV Prosta... | vorinostat laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | NCT01838187 | Neuroblastoma Pheochromocytom... Paraganglioma | I-131 MIBG Vorinostat | 12 Months - | Children's Hospital Medical Center, Cincinnati | |
| Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | NCT00948688 | Pancreatic Canc... Adenocarcinoma ... | Radiation thera... 5-FU Vorinostat | 18 Years - | Massachusetts General Hospital | |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | NCT01267240 | Paranasal Sinus... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph... | Capecitabine Vorinostat | 19 Years - | National Cancer Institute (NCI) | |
| Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | NCT00132028 | Adult Favorable... Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular L... Adult Nodular S... Adult Unfavorab... Recurrent Adult... | vorinostat laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT00392353 | Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Adult... Refractory Anem... | Azacitidine Laboratory Biom... Pharmacological... Vorinostat | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | NCT01267240 | Paranasal Sinus... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph... | Capecitabine Vorinostat | 19 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer | NCT01413750 | Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Paclitaxel Carboplatin Vorinostat Placebo Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer | NCT01084057 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat ixabepilone laboratory biom... pharmacological... | 18 Years - | City of Hope Medical Center | |
| Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | NCT02316340 | Colorectal Canc... | Vorinostat Hydroxychloroqu... Regorafenib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer | NCT01695057 | Stage II Breast... Stage IIIA Brea... Triple-negative... | vorinostat therapeutic con... laboratory biom... | 18 Years - | University of Southern California | |
| Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | NCT00278330 | Blastic Phase C... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Untreated Adult... Untreated Adult... | alvocidib vorinostat | 18 Years - | National Cancer Institute (NCI) | |
| Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery | NCT00662311 | Stage IIIA Non-... Stage IIIB Non-... | vorinostat paclitaxel radiation thera... | 18 Years - | University of Washington | |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | NCT03843528 | Acute Myeloid L... Myelodysplastic... Mixed Phenotype... Juvenile Myelom... | Vorinostat Azacitidine Inj... | 1 Year - 21 Years | Johns Hopkins All Children's Hospital | |
| Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | NCT03426891 | Glioblastoma Brain Tumor GBM | Pembrolizumab Vorinostat Temozolomide Radiotherapy | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies | NCT00691210 | Hodgkin's Disea... Non-Hodgkin's L... | Vorinostat Niacinamide Etoposide | 18 Years - | Columbia University | |
| Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | NCT02538510 | Head and Neck S... Recurrent Nasal... Recurrent Nasop... Recurrent Saliv... Squamous Cell C... Stage III Major... Stage III Nasal... Stage III Nasop... Stage IV Nasoph... Stage IVA Major... Stage IVA Nasal... Stage IVB Major... Stage IVB Nasal... Stage IVC Major... Stage IVC Nasal... | Laboratory Biom... Pembrolizumab Vorinostat | 18 Years - | University of Washington | |
| Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00918723 | Chronic Lymphoc... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage II Small ... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Fludarabine Pho... Cyclophosphamid... Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) | NCT00907738 | Advanced Cancer | vorinostat | 18 Years - | Merck Sharp & Dohme LLC | |
| Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | NCT00958074 | Cutaneous T-cel... Cutaneous T-cel... Cutaneous T-cel... Cutaneous T-cel... | vorinostat flow cytometry laboratory biom... | 18 Years - | University of Washington | |
| Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | NCT02349867 | Pancreatic Aden... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Recurrent Pancr... | Gemcitabine Sorafenib Vorinostat 3-Dimensional C... Intensity-Modul... RosetteSep DEPfff | 18 Years - | Virginia Commonwealth University | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer | NCT00719875 | Advanced Breast... | Vorinostat | 18 Years - | Yale University | |
| High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | NCT01378481 | Adult Anaplasti... Adult Anaplasti... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Recurrent Adult... | Vorinostat Stereotactic Ra... Laboratory Biom... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | NCT00910000 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Vorinostat Carboplatin Gemcitabine | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) | NCT00127140 | Lymphoma | vorinostat | 20 Years - 75 Years | Merck Sharp & Dohme LLC | |
| Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer | NCT00616967 | Breast Cancer | carboplatin paclitaxel albu... vorinostat placebo | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | NCT00473889 | Stage IIIB or I... | vorinostat Comparator: pac... Comparator: car... Comparator: pla... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) | NCT00127127 | Tumors | vorinostat | 20 Years - 75 Years | Merck Sharp & Dohme LLC | |
| Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors | NCT00324480 | Unspecified Adu... | alvocidib vorinostat pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | NCT02316340 | Colorectal Canc... | Vorinostat Hydroxychloroqu... Regorafenib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis | NCT01600742 | Brain Metastasi... | Vorinostat Placebo | 20 Years - | National Taiwan University Hospital | |
| A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) | NCT00907738 | Advanced Cancer | vorinostat | 18 Years - | Merck Sharp & Dohme LLC | |
| SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | NCT00787527 | Lymphoma | Zolinza (vorino... Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) | NCT01394354 | Multiple Myelom... | Vorinostat Bortezomib Doxorubicin Dexamethasone | 18 Years - | University Hospital Freiburg | |
| Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | NCT00810576 | Lymphoma | Vorinostat Bortezomib | 18 Years - | M.D. Anderson Cancer Center | |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | NCT02559778 | Neuroblastoma | Ceritinib dasatinib sorafenib vorinostat DFMO | - 22 Years | Milton S. Hershey Medical Center | |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | NCT03117751 | Acute Lymphobla... Acute Lymphobla... | Prednisone Vincristine Daunorubicin Pegaspargase Erwinase® Cyclophosphamid... Cytarabine Mercaptopurine Dasatinib Methotrexate Blinatumomab Ruxolitinib Bortezomib Dexamethasone Doxorubicin Etoposide Clofarabine Vorinostat Idarubicin Nelarabine Thioguanine Asparaginase Er... Calaspargase Pe... | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies | NCT00691210 | Hodgkin's Disea... Non-Hodgkin's L... | Vorinostat Niacinamide Etoposide | 18 Years - | Columbia University | |
| Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma | NCT01175980 | Recurrent Oral ... Recurrent Saliv... Salivary Gland ... Stage III Major... Stage III Oral ... Stage IVA Major... Stage IVA Oral ... Stage IVB Major... Stage IVB Oral ... Stage IVC Major... Stage IVC Oral ... Tongue Carcinom... | Laboratory Biom... Vorinostat | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | NCT00992446 | Adult Diffuse L... B-Cell Non-Hodg... Follicular Lymp... Mantle Cell Lym... Non-Hodgkin Lym... T-Cell Non-Hodg... | Autologous Hema... Bortezomib Carmustine Cytarabine Etoposide Melphalan Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | NCT00641706 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | vorinostat therapeutic con... bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | NCT03843528 | Acute Myeloid L... Myelodysplastic... Mixed Phenotype... Juvenile Myelom... | Vorinostat Azacitidine Inj... | 1 Year - 21 Years | Johns Hopkins All Children's Hospital | |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | NCT01500538 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... | Eltrombopag and... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | NCT01110876 | Brain Cancer Glioblastoma Mu... | Vorinostat Erlotinib Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer | NCT00262834 | Breast Cancer Stage I Breast ... Stage II Breast... Stage III Breas... | vorinostat conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | NCT02114502 | Myeloma | Carfilzomib SAHA Gemcitabine Busulfan Melphalan Stem Cell Trans... Palifermin Dexamethasone Caphosol Glutamine Pyridoxine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | NCT02316340 | Colorectal Canc... | Vorinostat Hydroxychloroqu... Regorafenib | 18 Years - | The University of Texas Health Science Center at San Antonio |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
